Sensydia Archives - Medical Design Sourcing

AI breakthroughs in medtech: 7 ways to enhance healthcare

[Image from Pixabay]

Whether it’s OpenAI’s ChatGPT, Microsoft’s new Bing or Google’s Bard, 2023 is the year when generative artificial intelligence entered the popular consciousness.

In the medtech space, it seems as though every company is seeking ways to incorporate some form of AI into the digital features of their products and services.

So what is artificial intelligence good at so far when it comes to advancing medtech and healthcare in general? Here are seven recent examples:

1. Helping physicians identify medical problems quickly

GI Genius’ AI-based enhancements place green boxes around areas that may need extra scrutiny during a colonoscopy, helping to prevent physicians from losing their focus. [Image courtesy of Medtronic]

Interest is growing in artificial intelligence that can help radiologists, gastroenterologists and othe…

Sensydia completes enrollment in study for AI-powered cardiac monitoring device

[Image from Sensydia]Sensydia announced today that it completed enrollment in its 225-subject development study for its AI-powered Cardiac Performance System (CPS).

Los Angeles-based Sensydia designed the AI-based, non-invasive CPS to use heart sound analysis. It may enable earlier detection and improved therapy guidance for heart failure and pulmonary hypertension patients.

CPS uses ultra-sensitive biosensors for the rapid, non-invasive measurement of a number of cardiac metrics. These include ejection fraction, cardiac output, pulmonary artery pressure and pulmonary capillary wedge pressure. It all comes together in one handheld device, Sensydia said.

Normally, patients must undergo echocardiography and invasive catheterization to obtain these measurements. CPS offers fast and safe measurements and can be performed almost anywhere with minimal training, according to a news release.

Sensydia conducted the study at the University of Pittsburgh Medica…

Sensydia wins FDA breakthrough nod to expand uses for its cardiac monitoring device

[Image from Sensydia]Sensydia announced today that it received FDA breakthrough device designation for its Cardiac Performance System (CPS).

Los Angeles-based Sensydia designed CPS as a non-invasive cardiac monitoring device that reports critical heart performance measurements to physicians for the comprehensive evaluation of patients with advanced and persistent heart failure. It can make the measurements without an in-hospital catheterization procedure or ultrasound assessment, according to the company

CPS already has FDA clearance for measuring ejection fraction — and can presently measure cardiac output, pulmonary artery pressure and pulmonary capillary wedge pressure simultaneously.

According to a news release, CPS uses ultra-sensitive biosensors to acquire heart sound data before applying machine learning to compute multiple hemodynamic measurements. The platform then delivers a comprehensive all-in-one report through its CPS iPad application.

…